Physician profile
Bhavna Bhat
NPI 1790746352
$1,829.19
in general payments reported to CMS, 2019-2025
26 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $65.25 · 2021: $95.80 · 2022: $217 · 2023: $221 · 2024: $401 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $407.71 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $296.96 | 2021-2025 | Eterna, Proclaim, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $183.40 | 2019-2021 | |
| Amgen INC. | $169.13 | 2019-2024 | Evenity, Prolia |
| Lilly USA, LLC | $147.06 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Biotronik Nro, INC. | $141.57 | 2024 | Prospera |
| Merck Sharp & Dohme LLC | $86.65 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amarin Pharma, INC. | $46.26 | 2019-2020 | |
| Abiomed | $30.51 | 2025 | |
| Daiichi Sankyo INC. | $29.73 | 2019-2023 | Injectafer |
| Grifols USA, LLC | $29.39 | 2019-2025 | Prolastin-C Liquid |
| Pfizer INC. | $25.80 | 2022-2023 | |
| Boston Scientific Corporation | $24.58 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.58 | 2024 | |
| Gilead Sciences, INC. | $21.77 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20.00 | 2023 | Qulipta, Ubrelvy |
| Shionogi INC | $17.52 | 2019 | |
| Medtronic USA, INC. | $17.06 | 2019 | |
| Glaxosmithkline, LLC. | $16.35 | 2024 | Arexvy, Shingrix |
| Phadia US INC. | $15.45 | 2024 | Immunocap |
| Sanofi Pasteur INC. | $14.94 | 2019 | |
| Echosens North America, INC. | $14.92 | 2025 | Fibroscan |
| Fresenius Kabi USA, LLC | $14.73 | 2023 | Idacio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.98 | 2022 | |
| Beta Bionics, INC. | $9.48 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhavna Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.